194 related articles for article (PubMed ID: 29427024)
1. Comparison of the effects of linagliptin and voglibose on endothelial function in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, pilot study (EFFORT).
Koyama T; Tanaka A; Yoshida H; Oyama JI; Toyoda S; Sakuma M; Inoue T; Otsuka Y; Node K
Heart Vessels; 2018 Aug; 33(8):958-964. PubMed ID: 29427024
[TBL] [Abstract][Full Text] [Related]
2. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial.
Sawada T; Tsubata H; Hashimoto N; Takabe M; Miyata T; Aoki K; Yamashita S; Oishi S; Osue T; Yokoi K; Tsukishiro Y; Onishi T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H; Yokoyama M
Cardiovasc Diabetol; 2016 Aug; 15(1):121. PubMed ID: 27565734
[TBL] [Abstract][Full Text] [Related]
3. Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP).
Fujitani Y; Fujimoto S; Takahashi K; Satoh H; Hirose T; Hiyoshi T; Ai M; Okada Y; Gosho M; Mita T; Watada H
Diabetes Res Clin Pract; 2016 Nov; 121():146-156. PubMed ID: 27710821
[TBL] [Abstract][Full Text] [Related]
4. Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.
Tripolt NJ; Aberer F; Riedl R; Url J; Dimsity G; Meinitzer A; Stojakovic T; Aziz F; Hödl R; Brachtl G; Strunk D; Brodmann M; Hafner F; Sourij H
Cardiovasc Diabetol; 2018 May; 17(1):71. PubMed ID: 29773079
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
Ayaori M; Iwakami N; Uto-Kondo H; Sato H; Sasaki M; Komatsu T; Iizuka M; Takiguchi S; Yakushiji E; Nakaya K; Yogo M; Ogura M; Takase B; Murakami T; Ikewaki K
J Am Heart Assoc; 2013 Jan; 2(1):e003277. PubMed ID: 23525426
[TBL] [Abstract][Full Text] [Related]
7. Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
Jones RB; Vickers SP; Cheetham SC; Headland KR; Mark M; Klein T
Eur J Pharmacol; 2014 Apr; 729():59-66. PubMed ID: 24530555
[TBL] [Abstract][Full Text] [Related]
8. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
[TBL] [Abstract][Full Text] [Related]
9. The effects of linagliptin on endothelial function and global arginine bioavailability ratio in coronary artery disease patients with early diabetes: study protocol for a randomized controlled trial.
Tripolt NJ; Aberer F; Riedl R; Hutz B; Url J; Dimsity G; Meinitzer A; Stojakovic T; Hödl R; Brodmann M; Hafner F; Sourij H
Trials; 2016 Oct; 17(1):495. PubMed ID: 27733180
[TBL] [Abstract][Full Text] [Related]
10. Effects of linagliptin monotherapy compared with voglibose on postprandial lipid profiles in Japanese patients with type 2 diabetes: linagliptin study of effects on postprandial blood glucose (L-STEP) sub-study 1.
Kurozumi A; Okada Y; Satoh H; Inoue I; Chimori H; Akita E; Shiraiwa T; Fujitani Y; Mita T; Gosho M; Watada H
Endocr J; 2018 Apr; 65(4):415-425. PubMed ID: 29367471
[TBL] [Abstract][Full Text] [Related]
11. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease.
Emoto T; Sawada T; Hashimoto M; Kageyama H; Terashita D; Mizoguchi T; Mizuguchi T; Motodi Y; Iwasaki M; Taira K; Okamoto H; Matsuo Y; Kim SK; Takarada A; Yokoyama M
Am J Cardiol; 2012 Jan; 109(1):42-6. PubMed ID: 21944671
[TBL] [Abstract][Full Text] [Related]
12. Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial.
Parthan G; Bhansali S; Kurpad AV; Walia R; Bhat K; Bhansali A
BMC Pharmacol Toxicol; 2018 Jul; 19(1):38. PubMed ID: 29970184
[TBL] [Abstract][Full Text] [Related]
13. Effect of Aggressive lipid-lowering treatment with Rosuvastatin on vascular endoTHelium function: evaluation of vascular endothelium function (EARTH study).
Takayama T; Hiro T; Yoda S; Fukamachi D; Haruta H; Kogo T; Mineki T; Murata H; Oshima T; Hirayama A
Heart Vessels; 2018 Jun; 33(6):590-594. PubMed ID: 29209775
[TBL] [Abstract][Full Text] [Related]
14. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
Hiki M; Shimada K; Kiyanagi T; Fukao K; Hirose K; Ohsaka H; Fukushima Y; Kume A; Matsumori R; Sumiyoshi K; Miyazaki T; Ohmura H; Kurata T; Miida T; Daida H
Circ J; 2010 Jul; 74(7):1471-8. PubMed ID: 20519875
[TBL] [Abstract][Full Text] [Related]
15. Effects of linagliptin versus voglibose on treatment-related quality of life in patients with type 2 diabetes: sub-analysis of the L-STEP study.
Goto H; Mita T; Fujitani Y; Fujimoto S; Takahashi K; Satoh H; Hirose T; Hiyoshi T; Ai M; Okada Y; Nishimura H; Kuroda H; Matsubara T; Gosho M; Ishii H; Watada H
Endocr J; 2018 Jun; 65(6):657-668. PubMed ID: 29643323
[TBL] [Abstract][Full Text] [Related]
16. Effect of Sitagliptin on Coronary Flow Reserve Assessed by Magnetic Resonance Imaging in Type 2 Diabetic Patients With Coronary Artery Disease.
Moriwaki K; Takeuchi T; Fujimoto N; Sawai T; Sato Y; Kumagai N; Masuda J; Nakamori S; Ishida M; Yamada N; Nakamura M; Sakuma H; Ito M; Dohi K
Circ J; 2018 Jul; 82(8):2119-2127. PubMed ID: 29760346
[TBL] [Abstract][Full Text] [Related]
17. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Nakamura K; Oe H; Kihara H; Shimada K; Fukuda S; Watanabe K; Takagi T; Yunoki K; Miyoshi T; Hirata K; Yoshikawa J; Ito H
Cardiovasc Diabetol; 2014 Jul; 13():110. PubMed ID: 25074318
[TBL] [Abstract][Full Text] [Related]
18. Effects of sitagliptin on exercise capacity and hemodynamics in patients with type 2 diabetes mellitus and coronary artery disease.
Fujimoto N; Moriwaki K; Takeuchi T; Sawai T; Sato Y; Kumagai N; Masuda J; Nakamori S; Ito M; Dohi K
Heart Vessels; 2020 May; 35(5):605-613. PubMed ID: 31641887
[TBL] [Abstract][Full Text] [Related]
19. Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus.
Ihana-Sugiyama N; Yamamoto-Honda R; Sugiyama T; Tsujimoto T; Kakei M; Noda M
Med Sci Monit Basic Res; 2017 Feb; 23():36-44. PubMed ID: 28242866
[TBL] [Abstract][Full Text] [Related]
20. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
Yamada H; Tanaka A; Kusunose K; Amano R; Matsuhisa M; Daida H; Ito M; Tsutsui H; Nanasato M; Kamiya H; Bando YK; Odawara M; Yoshida H; Murohara T; Sata M; Node K;
Cardiovasc Diabetol; 2017 May; 16(1):63. PubMed ID: 28490337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
